Q1: What sterile manufacturing capabilities does Eramol offer for Phase I and Phase II clinical trials?
Eramol provides GMP sterile liquid manufacturing for 2 mL and 10 mL clinical vials, supporting early-phase programmes requiring aseptic precision and regulatory alignment.
Our new sterile facility includes aseptic isolator technology, Grade A/C cleanrooms, and terminal sterilisation capability, enabling us to handle a wide range of investigational products for Phase I and II.
This integrated approach ensures high-quality, compliant, inspection-ready batches for injectable clinical development.
Q2: What batch sizes and throughput can Eramol support for sterile vial production?
The facility is designed for 24/7 shift operation, delivering >1,000 sterile vials per day depending on formulation and fill volume.
Whether aseptic or terminally sterilised, every batch benefits from rigorous quality control, QP alignment, in-process monitoring, and validated processes.
Combined with on-site packaging, labelling, QP release, storage, and global distribution, Eramol offers a true end-to-end sterile vial manufacturing solution.